It would amass a huge amount of data, he suggested, collecting information from medical claims, wearable devices, and more to provide real-time coverage of where autism is appearing and what ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. | Pfizer has jettisoned yet ...

Programming Languages | News, how-tos, features, reviews, and videos ...